PC
PCRX.V
—
TSX Venture
Pharmaceuticals
Pharma Corp Rx Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
0,08
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
PharmaCorp Rx Inc operates in the drug retailing sector, providing pharmaceutical products and related services to consumers.
Business. PharmaCorp Rx Inc (PCRX.V) is a drug retailer operating within the Food & Drug Retailing industry. The company generates revenue through product sales and is listed on the TSX Venture Exchange. Specific details regarding operating segments, headquarters location, and geographic mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target0,57
Analyst recommendations
2 analysts · consensus BuyBuy2
Hold0
Sell0
12-month price target
0,57
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
2 analysts · indicative
Ownership→
American Century Investment Management, Inc.
largest disclosed fund holder
Profitability
—
not yet wired
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to PCRX.V. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
PharmaCorp Rx Inc (PCRX.V) is a drug retailer operating within the Food & Drug Retailing industry. The company generates revenue through product sales and is listed on the TSX Venture Exchange. Specific details regarding operating segments, headquarters location, and geographic mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals
AI synthesis
GENERATEDPharmaCorp Rx Inc maintains a strong liquidity position, with CAD 25.89 million in cash and equivalents, representing a significant portion of its total assets. The company's debt-to-equity ratio of 0.08 indicates a conservative capital structure, with total liabilities of CAD 13.65 million compared to total equity of CAD 52.27 million. This low leverage supports financial flexibility and reduces exposure to interest rate fluctuations.
The company's profitability is reflected in its operating cash flow of CAD 2.01 million, which, while modest, supports ongoing operations and capital expenditures. However, the operating cash flow is relatively low compared to the company's revenue of CAD 20.89 million, suggesting potential inefficiencies or high operating costs. The capital expenditure of CAD -87,600 indicates minimal investment in new assets, which may limit future growth opportunities.
PharmaCorp Rx Inc's revenue is concentrated in the drug retailing segment, with no disclosed geographic diversification. This concentration increases the company's vulnerability to regional economic downturns or regulatory changes affecting the pharmaceutical retail market. The lack of geographic diversification is a notable risk factor, as it limits the company's ability to offset losses in one region with gains in another.
The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial data. Analysts have set a mean price target of CAD 0.57, with a median of CAD 0.57, indicating a neutral outlook. The absence of strong buy recommendations and the limited number of buy ratings suggest that the market does not anticipate substantial growth in the near term.
Risk factors for PharmaCorp Rx Inc include low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt levels and strong cash reserves mitigate liquidity concerns. However, the lack of capital expenditures and the conservative capital structure may limit long-term growth potential. The dilution risk is also low, with no significant dilution sources identified in the latest filings.
Recent events and filings do not indicate any major changes in the company's operations or financial strategy. The company continues to operate within its established business model, with no significant new product launches or market expansions reported. The absence of recent events suggests a stable but potentially stagnant business environment.
Key takeaways
- PharmaCorp Rx Inc maintains a conservative capital structure with a low debt-to-equity ratio of 0.08.
- The company's operating cash flow is modest, indicating potential inefficiencies or high operating costs.
- Revenue is concentrated in the drug retailing segment, increasing vulnerability to regional economic and regulatory changes.
- Analysts have a neutral outlook, with a mean price target of CAD 0.57 and no strong buy recommendations.
- The company's low liquidity and dilution risks are mitigated by strong cash reserves and minimal debt.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$0,52
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
—
Net cashⓘ
$21.7M
Current ratioⓘ
—
Debt / equityⓘ
0.1
ROAⓘ
—
ROEⓘ
—
Cash conversionⓘ
—
CapEx / revenueⓘ
-0.4%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Injectable Anesthetics79,0 %
low · business_description · 2026-07-03
Corticosteroid Injections—
low · business_description · 2026-07-03
Business relationships
Business relationships9 disclosed relationships · 2 types · extracted from filings & disclosures
Partners3
Subsidiaries6
EX21:46b22af37c1dEX21:46b22af37c1dSubsidiarie97%
EX21:479e52d5b879EX21:479e52d5b879Subsidiarie97%
EX21:5834e4902983EX21:5834e4902983Subsidiarie97%
EX21:58c9fe208833EX21:58c9fe208833Subsidiarie97%
EX21:62c0df29cee1EX21:62c0df29cee1Subsidiarie97%
EX21:fbba07e2f255EX21:fbba07e2f255Subsidiarie97%
Supply chain
Vendors → PCRX ↔ Partners → Customers · click any node to drill
3 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
Peer comparison8 peers · vs PCRX · multiples and returns
JN
JNJ—
Johnson & Johnson
$254,43
622,1B USDP/E
23,5x
-107,9 vs self
Div yield
2,0 %
— vs self
ROE
33,0 %
+32,0 vs self
LL
LLY—
ELI LILLY AND COMPANY
$1 124,04
1,01T USDP/E
52,0x
-79,3 vs self
Div yield
0,5 %
— vs self
ROE
66,2 %
+65,1 vs self
MR
MRK—
MERCK & CO., INC.
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
PF
PFE—
Pfizer Inc
$25,05
143,6B USDP/E
18,2x
-113,1 vs self
Div yield
6,9 %
— vs self
ROE
8,6 %
+7,6 vs self
AB
ABBV—
Abbvie Inc
$245,10
434,8B USDP/E
110,6x
-20,7 vs self
Div yield
2,5 %
— vs self
ROE
-63,5 %
-64,5 vs self
AZ
AZN—
AZN.L
$157,59
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BM
BMY—
Bristol-myers Squibb Co
$65,60
134,3B USDP/E
17,7x
-113,6 vs self
Div yield
4,1 %
— vs self
ROE
31,6 %
+30,6 vs self
GS
GSK—
Gsk Plc-spon Adr
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
0,01
Predicted surprise
+0,00
Beat probability
45 %
Analysts
2
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-15 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,01 |
| Revenue | —no estimate | —no estimate | 53,7M CAD |
| Operating income | —no estimate | —no estimate | —no estimate |
Full-year consensus mean (period as reported by source) · consensus in CAD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution2 analysts
Strong buy0
Buy2
Hold0
Sell0
Strong sell0
12-month price target$0,57 · Median $0,57
Low $0,50High $0,65
EPS surprise
−166,7 %
reported vs consensus · miss
Revenue surprise
−61,1 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$0,50
Mean$0,57
Median$0,57
High$0,65
Spot$0,52
+10.6 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Capex / Rev-0,4 %Above P75
D/E0,08Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 83 912 sh4 exercises · 8 grants9 insiders
- Director · Stock Option (Right to Buy) → Common StockAcquired 10 891 @ $23,42grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 10 891 @ $23,42grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 10 891 @ $23,42grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 10 891 @ $23,42grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 32 675 @ $23,42grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 10 891 @ $23,42grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 10 891 @ $23,42grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 10 891 @ $23,42grant · 2026-06-10
- Chief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 12 941 @ $16,45exercise · 2026-04-23
- Chief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 1 500 @ $16,45exercise · 2026-04-22
- Chief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 2 845 @ $16,45exercise · 2026-04-21
- Chief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 7 714 @ $16,45exercise · 2026-04-20
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
Source documents
- PharmaCorp Rx Inc Market data — financials · 2026-05-28
- PharmaCorp Rx Inc Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,01 %$19M
- Investment Managers · as of 2026-03-310,01 %$47M
- Investment Managers · as of 2024-06-300,01 %$229M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$35M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2024-12-310,00 %$12M
- Investment Managers · as of 2026-03-310,00 %$17M
- Investment Managers · as of 2026-03-310,00 %$13M
- Investment Managers · as of 2026-03-310,00 %$11M
- Investment Managers · as of 2026-03-310,00 %$31M
- Investment Managers · as of 2025-12-310,00 %$125M
- Investment Managers · as of 2026-03-310,00 %$26M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$12M
- Investment Managers · as of 2026-03-310,00 %$43M
- Institutional Investor · as of 2026-03-310,00 %$7M
- Institutional Investor · as of 2026-03-310,00 %$4M
- Funds · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Net selling0 buys · 10 sellsnet -$1,4M13 insiders · last 365d
- Senior Vice President, Finance · Common StockSold 6 115 @ $23,50$144K · 2026-06-11
- Director · Common StockOther 6 405 · 2026-06-10
- Director · Common StockOther 6 405 · 2026-06-10
- Director · Common StockOther 6 405 · 2026-06-10
- Director · Common StockOther 6 405 · 2026-06-10
- Director · Common StockOther 6 405 · 2026-06-10
- Director · Common StockOther 6 405 · 2026-06-10
- Director · Common StockOther 6 405 · 2026-06-10
- Chief Administrative Officer · Common StockSold 10 259 @ $22,27$228K · 2026-06-04
- Chief Administrative Officer · Common StockOther 8 528 @ $22,32$190K · 2026-06-03
- Chief Medical Officer · Common StockOther 4 728 @ $22,32$106K · 2026-06-03
- Senior Vice President, Finance · Common StockOther 3 187 @ $22,32$71K · 2026-06-03
- Chief Financial Officer · Common StockOther 12 941 @ $16,45$213K · 2026-04-23
- Chief Financial Officer · Common StockSold 12 941 @ $25,16$326K · 2026-04-23
- Chief Financial Officer · Common StockOther 1 500 @ $16,45$25K · 2026-04-22
- Chief Financial Officer · Common StockSold 1 500 @ $25,01$38K · 2026-04-22
- Chief Financial Officer · Common StockOther 2 845 @ $16,45$47K · 2026-04-21
- Chief Financial Officer · Common StockSold 2 845 @ $25,01$71K · 2026-04-21
- Chief Financial Officer · Common StockSold 7 714 @ $25,14$194K · 2026-04-20
- Chief Financial Officer · Common StockOther 7 714 @ $16,45$127K · 2026-04-20
- Chief Medical Officer · Common StockSold 3 261 @ $22,82$74K · 2026-03-17
- Director · Common StockSold 500 @ $21,81$11K · 2026-03-17
- Chief Administrative Officer · Common StockOther 54 546 · 2026-02-11
- Chief Financial Officer · Common StockOther 49 091 · 2026-02-11
- Chief Commercial Officer · Common StockOther 51 714 · 2026-02-11
Short positioning
7.0Mshares short+5.7% vs prior
15.78days to cover
34.2%short of daily vol
183fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
PCRX.VCanonical
TSX Venture · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorPartnersSubsidiaries
Evidence & claims
From filings & derived data- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -42.7%Derived (calculated)
- Net margin (FY 2025-12-31): 1.0%Derived (calculated)
- Return on equity (FY 2025-12-31): 1.0%Derived (calculated)
- Return on assets (FY 2025-12-31): 0.6%Derived (calculated)
- Current ratio (FY 2025-12-31): 4.54xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.82xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 44.2%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -12.1%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 107.4%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 107.4%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 107.0%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -19.7%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 126.2%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 43.8%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 3.6%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -11.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -18.6%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -26.2%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -36.4%Derived (calculated)
- EPS (diluted) (annual): USD-PER-SHARES 0SEC XBRL filing
- R&D expense (annual): USD 117.31MSEC XBRL filing
- Operating income (annual): USD 19.19MSEC XBRL filing
- Operating cash flow (annual): USD 151.99MSEC XBRL filing
- Total liabilities (annual): USD 571.81MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-08-04 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-11 00:00 UTCINSIDER20 insider transactions — 2026-06 · net sell $739k 8 derivative
2026-06-11INSIDERRIKER LAUREN sold 6.1k sh — Senior Vice President, Finance ~$144k
2026-06-10INSIDERHirawat Samit transacted 6.4k sh — Director
2026-06-10INSIDERCHRISTIE CHRISTOPHER transacted 6.4k sh — Director
2026-06-10INSIDERYoung Alethia transacted 6.4k sh — Director
2026-06-10INSIDERYANG MICHAEL J. transacted 6.4k sh — Director
2026-06-10INSIDERBIGAL MARCELO transacted 6.4k sh — Director
2026-06-10INSIDERFroimson Mark transacted 6.4k sh — Director
2026-06-10INSIDERBrege Laura transacted 6.4k sh — Director
2026-06-10INSIDERHirawat Samit acquired 10.9k sh Stock Option (Right to Buy) — Director
2026-06-10INSIDERWIGGANS THOMAS G acquired 32.7k sh Stock Option (Right to Buy) — Director
2026-06-10INSIDERBrege Laura acquired 10.9k sh Stock Option (Right to Buy) — Director
2026-06-10INSIDERFroimson Mark acquired 10.9k sh Stock Option (Right to Buy) — Director
2026-06-10INSIDERBIGAL MARCELO acquired 10.9k sh Stock Option (Right to Buy) — Director
2026-06-10INSIDERYANG MICHAEL J. acquired 10.9k sh Stock Option (Right to Buy) — Director
2026-06-10INSIDERYoung Alethia acquired 10.9k sh Stock Option (Right to Buy) — Director
2026-06-10INSIDERCHRISTIE CHRISTOPHER acquired 10.9k sh Stock Option (Right to Buy) — Director
2026-06-04INSIDERWILLIAMS KRISTEN sold 10.3k sh — Chief Administrative Officer ~$228k
2026-06-03INSIDERWILLIAMS KRISTEN transacted 8.5k sh — Chief Administrative Officer ~$190k
2026-06-03INSIDERSLONIN JONATHAN transacted 4.7k sh — Chief Medical Officer ~$106k
2026-06-03INSIDERRIKER LAUREN transacted 3.2k sh — Senior Vice President, Finance ~$71k
2026-04-23 00:00 UTCINSIDER12 insider transactions — 2026-04 · net sell $217k 4 derivative
2026-04-23INSIDERCross Shawn transacted 12.9k sh — Chief Financial Officer ~$213k
2026-04-23INSIDERCross Shawn sold 12.9k sh — Chief Financial Officer ~$326k
2026-04-23INSIDERCross Shawn disposed of 12.9k sh Stock Option (Right to Buy) — Chief Financial Officer
2026-04-22INSIDERCross Shawn transacted 1.5k sh — Chief Financial Officer ~$25k
2026-04-22INSIDERCross Shawn sold 1.5k sh — Chief Financial Officer ~$38k
2026-04-22INSIDERCross Shawn disposed of 1.5k sh Stock Option (Right to Buy) — Chief Financial Officer
2026-04-21INSIDERCross Shawn transacted 2.8k sh — Chief Financial Officer ~$47k
2026-04-21INSIDERCross Shawn sold 2.8k sh — Chief Financial Officer ~$71k
Showing the 40 most recent of 61 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage